Neutropenic Fever Syndromes in Patients Undergoing Cytotoxic Therapy for Acute Leukemia and Myelodysplastic Syndromes

Seminars in Hematology

Volumn 46, Issue 3, 2009, Pages 259-268

  Bow, E J ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBENICILLIN; CEFALOTIN; CEPHALOSPORIN DERIVATIVE; CYTOTOXIC AGENT; HEMOPOIETIC GROWTH FACTOR; METICILLIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ACUTE LEUKEMIA; ANTIBIOTIC RESISTANCE; APLASIA; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BODY TEMPERATURE MEASUREMENT; CLINICAL TRIAL; DISEASE COURSE; FEBRILE NEUTROPENIA; GRAM POSITIVE INFECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTIPLE CYCLE TREATMENT; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPHIL COUNT; NONHUMAN; PATIENT CARE PLANNING; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; UNSPECIFIED SIDE EFFECT; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTINEOPLASTIC AGENTS; BACTERIAL INFECTIONS; CYTOTOXINS; FEVER; HUMANS; LEUKEMIA; MYCOSES; MYELODYSPLASTIC SYNDROMES; NEUTROPENIA; RECURRENCE; SYNDROME;

EID: 67249091697     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2009.03.002     Document Type: Article

References (96)

1. Bodey G.P., Buckley M., Sathe Y.S., and Freireich E.J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 64 (1966) 328-340
2. Bodey G.P., Rodriguez V., Chang H.Y., and Narboni G. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 41 (1978) 1610-1622
3. Leese B., Collin R., and Clark D.J. The costs of treating febrile neutropenia in patients with malignant blood disorders. Pharmacoeconomics 6 (1994) 233-239
4. Elting L.S., and Shih Y.C. The economic burden of supportive care of cancer patients. Support Care Cancer 12 (2004) 219-226
5. Hughes W.T., Armstrong D., Bodey G.P., Bow E.J., Brown A.E., Calandra T., et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 34 (2002) 730-751
6. Link H., Bohme A., Cornely O.A., Hoffken K., Kellner O., Kern W.V., et al. Antimicrobial therapy of unexplained fever in neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol. 82 Suppl 2 (2003) S105-S117
7. Bow E.J. Infectious complications in patients receiving cytotoxic therapy for acute leukemia: History, background and approaches to managment. In: Wingard J.R., and Bowden R.A. (Eds). Management of infection in oncology patients (2003), Martin Dunitz, London 71-104
8. Buchheidt D., Bohme A., Cornely O.A., Fatkenheuer G., Fuhr H.G., Heussel G., et al. Diagnosis and treatment of documented infections in neutropenic patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 82 Suppl 2 (2003) S127-S132
9. Santolaya M.E., Rabagliati R., Bidart T., Paya E., Guzman A.M., Morales R., et al. Consensus: Rational approach towards the patient with cancer, fever and neutropenia. Rev Chilena Infectol. 22 Suppl 2 (2005) S79-S113
10. Tamura K. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group. Int J Antimicrob Agents 26 Suppl 2 (2005) S123-S127
11. Freifeld A.G., Segal B.H., Baden L.R., Brown A.E., Caspar C., deShazzo M., et al. Prevention and treatment of cancer-related infections. National Comprehensive Cancer Network-Clinical Practice Guidelines in Oncology v2. April 9, 2007. http://www.nccn.org/professionals/physcian_gls/PDF/infections.pdf
12. EORTC International Antimicrobial Therapy Cooperative Project Group. Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 137 (1978) 14-29
13. Blay J.Y., Chauvin F., Le Cesne A., Anglaret B., Bouhour D., Lasset C., et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 14 (1996) 636-643
14. Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 39 Suppl 1 (2004) S49-S52
15. Mackowiak P.A., Wasserman S.S., and Levine M.M. A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA 268 (1992) 1578-1580
16. Ciuraru N.B., Braunstein R., Sulkes A., and Stemmer S.M. The influence of mucositis on oral thermometry: when fever may not reflect infection. Clin Infect Dis. 46 (2008) 1859-1863
17. Mendes A.V., Sapolnik R., and Mendonca N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (Rio J) 83 (2007) S54-S63
18. Bodey G.P. The treatment of febrile neutropenia: from the Dark Ages to the present. Support Care Cancer 5 (1997) 351-357
19. Curtin J.A., and Marshall Jr. B.D. Use of antibiotics in cancer and leukemia. J Chronic Dis. 15 (1962) 713-718
20. Schimpff S.C., Satterlee W., Young V.M., and Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 284 (1971) 1061-1065
21. Schimpff S.C., Young V.M., Greene W.H., Vermeulen G.D., Moody M.R., Wiernik P.H., et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 77 (1972) 707-714
22. Bow E.J. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. Clin Microbiol Infect. 11 Suppl 5 (2005) 24-29
23. Marie J.P., Vekhoff A., Pico J.L., Guy H., Andremount A., Richet H., et al. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients. J Antimicrobial Chemother. 41 Suppl D (1998) 57-64
24. Zinner S.H. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 29 (1999) 490-494
25. Wisplinghoff H., Cornely O.A., Moser S., Bethe U., Stutzer H., Salzberger B., et al. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol. 24 (2003) 905-911
26. Morris P.G., Hassan T., McNamara M., Hassan A., Wiig R., Grogan L., et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Support Care Cancer 16 (2008) 1085-1088
27. Weinstock D.M., Conlon M., Iovino C., Aubrey T., Gudiol C., Riedel E., et al. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 13 (2007) 615-621
28. Carratala J., Roson B., Fernandez-Sevilla A., Alcaide F., and Gudiol F. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome. Arch Intern Med. 158 (1998) 868-872
29. Cattaneo C., Quaresmini G., Casari S., Capucci M.A., Micheletti M., Borlenghi E., et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 61 (2008) 721-728
30. Chen C.Y., Tang J.L., Hsueh P.R., Yao M., Huang S.Y., Chen Y.C., et al. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. J Formos Med Assoc. 103 (2004) 526-532
31. Aubron C., Poirel L., Fortineau N., Nicolas P., Collet L., Nordmann P., et al. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist 11 (2005) 254-259
32. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic managment of the neutropenic patient. J Infect Dis. 161 (1990) 397-401
33. Bow E.J., Rotstein C., Noskin G.A., Laverdiere M., Schwarer A.P., Segal B.H., et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis. 43 (2006) 447-459
34. Pizzo P.A. Fever in immunocompromised patients. N Engl J Med 341 (1999) 893-900
35. Cometta A., Calandra T., Gaya H., Zinner S.H., De Bock R., Del Favero A., et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program. Antimicrob Agents Chemother. 40 (1996) 1108-1115
36. Cometta A., Zinner S., De Bock R., Calandra T., Gaya H., Klastersky J., et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother. 39 (1995) 445-452
37. Akova M., Paesmans M., Calandra T., and Viscoli C. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis. 40 (2005) 239-245
38. Gerson S.L., Talbot G.H., Hurwitz S., Strom B.L., Lusk E.J., Cassileth P.A., et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 100 (1984) 345-351
39. Nucci M., Spector N., Bueno A.P., Solza C., Perecmanis T., Bacha P.C., et al. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis. 24 (1997) 575-579
40. Sickles E.A., Greene W.H., and Wiernik P.H. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 135 (1975) 715-719
41. Sickles E.A., Greene W.H., and Wiernik P.H. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 135 (1975) 715-719
42. Sickles E.A., Young V.M., Greene W.H., and Wiernik P.H. Pneumonia in acute leukemia. Ann Intern Med. 79 (1973) 528-534
43. Gardner A., Mattiuzzi G., Faderl S., Borthakur G., Garcia-Manero G., Pierce S., et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 26 (2008) 5684-5688
44. Peacock J.E., Herrington D.A., Wade J.C., Lazarus H.M., Reed M.D., Sinclair J.W., et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med. 137 (2002) 77-87
45. Bucaneve G., Micozzi A., Menichetti F., Martino P., Dionisi M.S., Martinelli G., et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 353 (2005) 977-987
46. Rubenstein E.B., Peterson D.E., Schubert M., Keefe D., McGuire D., Epstein J., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 (2004) 2026-2046
47. Bochud P.-Y., Eggiman P., Calandra T., Van Melle G., Saghafi L., Francioli P., et al. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 18 (1994) 25-31
48. Sonis S.T., Oster G., Fuchs H., Bellm L., Bradford W.Z., Edelsberg J., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 19 (2001) 2201-2205
49. Bow E.J., Loewen R., Cheang M.S., Shore T.B., Rubinger M., Schacter B., et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 15 (1997) 2254-2261
50. Bow E.J., and Meddings J.B. Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia. Leukemia 20 (2006) 2087-2092
51. Meropol N.J., Somer R.A., Gutheil J., Pelley R.J., Modiano M.R., Rowinsky E.K., et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 21 (2003) 1452-1458
52. Spielberger R., Stiff P., Bensinger W., Gentile T., Weisdorf D., Kewalramani T., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 351 (2004) 2590-2598
53. Wardley A.M., Jayson G.C., Swindell R., Morgenstern G.R., Chang J., Bloor R., et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol. 110 (2000) 292-299
54. Klastersky J., Paesmans M., Rubenstein E.B., Boyer M., Elting L., Feld R., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 18 (2000) 3038-3051
55. Freifeld A. Guidelines for Antimicrobials in Neutropenic Cancer Patients. Presented at the 45th Annual Meeting of the Infectious Diseases Society of America, October 4-7, 2007; San Diego, CA.
56. De Pauw B.E., Deresinski S.C., Feld R., Lane-Allman E.F., and Donnelly J.P. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med. 120 (1994) 834-844
57. Feld R., De Pauw B., Berman S., Keating A., and Ho W. Meropenem versus ceftazidime in the treatment of cancer patients with febrile neutropenia: a randomized, double-blind trial. J Clin Oncol. 18 (2000) 3690-3698
58. Stein R.S., Kayser J., and Flexner J.M. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia. Cancer 50 (1982) 2247-2251
59. Pizzo P.A., Robichaud K.J., Gill F.A., and Witebsky F.G. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 72 (1982) 101-111
60. EORTC International Antimicrobial Therapy Project Group. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med. 86 (1989) 668-672
61. Slavin M.A., Szer J., Grigg A.P., Roberts A.W., Seymour J.F., Sasadeusz J., et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J. 34 (2004) 192-200
62. Yoshida M., and Ohno R. Current antimicrobial usage for the management of infections in leukemic patients in Japan: results of a survey. Clin Infect Dis. 39 Suppl 1 (2004) S11-S14
63. Marchetti O., Cordonnier C., and Calandra T. Empirical antifungal therapy in neutropaenic cancer patients with persistent fever. Eur J Cancer Suppl. 5 (2007) 32-42
64. O'Hanley P., Easaw J., Rugo H., and Easaw S. Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med. 87 (1989) 605-613
65. Bow E.J., Kilpatrick M.G., Scott B.A., Clinch J.J., and Cheang M.S. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome. Cancer 74 (1994) 52-60
66. Bow E.J., Loewen R., Cheang M.S., and Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 21 (1995) 361-369
67. Bow E.J., Sutherland J.A., Kilpatrick M.G., Williams G.J., Clinch J.J., Shore T.B., et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol. 14 (1996) 1345-1352
68. Bow E.J., Gallant G., Williams G.J., Woloschuk D., Shore T.B., Rubinger M., et al. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide and carboplatin. Cancer 83 (1998) 1344-1354
69. Maertens J., Theunissen K., Verhoef G., Verschakelen J., Lagrou K., Verbeken E., et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 41 (2005) 1242-1250
70. Kanda Y., Yamamoto R., Chizuka A., Hamaki T., Suguro M., Arai C., et al. Prophylactic action of oral fluconazole against infection in neutropenic patients-a meta-analysis of 16 randomized, controlled trials. Cancer 89 (2000) 1611-1625
71. Bow E.J., Laverdiere M., Lussier N., Rotstein C., Cheang M.S., Ioannou S., et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer 94 (2002) 3230-3246
72. Cornely O.A., Maertens J., Winston D.J., Perfect J., Ullmann A.J., Walsh T.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 356 (2007) 348-359
73. Walsh T.J., Finberg R.W., Arndt C., Hiemenz J., Schwartz C., Bodensteiner D., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 340 (1999) 764-771
74. Walsh T.J., Pappas P., Winston D.J., Lazarus H.M., Petersen F., Raffalli J., et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 346 (2002) 225-234
75. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 351 (2004) 1391-1402
76. Schiel X., Link H., Maschmeyer G., Glass B., Cornely O.A., Buchheidt D., et al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) multicenter trial II. Infection 34 (2006) 118-126
77. Bow E.J., Laverdière M., and Rotstein C. A systematic review of the efficacy of azoles and lipid-based formulations of amphotericin B as empirical anti-fungal therapy in persistently febrile neutropenic patients despite broad-spectrum anti-bacterial therapy. [abstract 702]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (2000) 364
78. Goldberg E., Gafter-Gvili A., Robenshtok E., Leibovici L., and Paul M. Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer 44 (2008) 2192-2203
79. Girois S.B., Chapuis F., Decullier E., and Revol B.G. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis. 24 (2005) 119-130
80. Caillot D., Couaillier J.F., Bernard A., Casasnovas O., Denning D.W., Mannone L., et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 19 (2001) 253-259
81. Almyroudis N.G., Kontoyiannis D.P., Sepkowitz K.A., de Pauw T.J., Walsh B.E., Segal B.H., et al. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection. Clin Infect Dis. 43 (2006) 1449-1455
82. Miceli M.H., Maertens J., Buve K., Grazziutti M., Woods G., Rahman M., et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 110 (2007) 112-120
83. Shelburne S.A., Hamill R.J., Rodriguez-Barradas M.C., Greenberg S.B., Atmar R.L., Musher D.W., et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81 (2002) 213-227
84. Robertson J., Meier M., Wall J., Ying J., and Fichtenbaum C.J. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 42 (2006) 1639-1646
85. Wright D.G., Robichaud K.J., Pizzo P.A., and Deisseroth A.B. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 304 (1981) 1185-1189
86. Bow E.J., Schroeder M.L., and Louie T.J. Pulmonary complications in patients receiving granulocyte transfusions and amphotericin B. Can Med Assoc J. 130 (1984) 593-597
87. Dana B.W., Durie B.G., White R.F., and Huestis D.W. Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: absence of significant pulmonary toxicity. Blood 57 (1981) 90-94
88. Karp D.D., Ervin T.J., Tuttle S., Gorgone B.C., Lavin P., Yunis E.J., et al. Pulmonary complications during granulocyte transfusions: incidence and clinical features. Vox Sang. 42 (1982) 57-61
89. Albelda S.M., Talbot G.H., Gerson S.L., Miller W.T., and Cassileth P.A. Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia. Am Rev Respir Dis. 131 (1985) 115-120
90. Martino P., Girmenia C., Venditti M., Micozzi A., Gentile G., Raccah R., et al. Spontaneous pneumothorax complicating pulmonary mycetoma in patients with acute leukemia. Rev Infect Dis. 12 (1990) 611-617
91. Pagano L., Ricci P., Nosari A., Tonso A., Buelli M., Montillo M., et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto). Br J Haematol. 89 (1995) 500-505
92. Todeschini G., Murari C., Bonesi R., Pizzolo G., Verlato G., Tecchio C., et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest. 29 (1999) 453-457
93. Takahashi Y., Kobayashi Y., Chikayama S., Ikeda M., and Kondo M. Effect of granulocyte/colony-stimulating factor on the onset of the adult respiratory distress syndrome. Acta Haematol. 101 (1999) 124-129
94. Takuma T., Okada K., Uchida Y., Yamagata A., and Sawae Y. Invasive pulmonary aspergillosis resulting in respiratory failure during neutrophil recovery from postchemotherapy neutropenia in three patients with acute leukaemia. J Intern Med. 252 (2002) 173-177
95. Maertens J., Theunissen K., Deeren D., Meersseman W., and Van E.J. Defining a case of invasive aspergillosis by serum galactomannan. Med Mycol. 44 Suppl (2006) 173-178
96. Shibuya K., Ando T., Hasegawa C., Wakayama M., Hamatani S., Hatori T., et al. Pathophysiology of pulmonary aspergillosis. J Infect Chemother. 10 (2004) 138-145